Prognostic Value and Significant Pathway Exploration Associated with TOP2A Involved in Papillary Thyroid Cancer

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Li WB, Zhou J, Xu L, et al. Identification of genes associated with Papillary Thyroid Carcinoma (PTC) for diagnosis by integrated analysis. Horm Metab Res. 2016;48(04):226–231. doi:10.1055/s-0035-1569289
   PubMed Web of Science ®Google Scholar
• Toniato A, Boschin I, Casara D, et al. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15(5):1518–1522. doi:10.1245/s10434-008-9859-4
   PubMed Web of Science ®Google Scholar
• Jain M, Zhang L, He M, et al. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(3):361–370. doi:10.1530/ERC-12-0403
   PubMed Web of Science ®Google Scholar
• Wang J, Yang H, Si Y, et al. Iodine promotes tumorigenesis of thyroid cancer by suppressing Mir-422a and up-regulating MAPK1. Cell Physiol Biochem. 2017;43(4):1325–1336. doi:10.1159/000481844
   PubMedGoogle Scholar
• Lynch BJ, Guinee DG Jr., Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. 1997;28(10):1180–1188. doi:10.1016/S0046-8177(97)90256-2
   PubMed Web of Science ®Google Scholar
• Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer. 1997;75(9):1340–1346. doi:10.1038/bjc.1997.227
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhang G, Wang P, et al. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol. 2017;17(1):2. doi:10.1186/s12876-016-0561-x
   PubMed Web of Science ®Google Scholar
• Zheng H, Li X, Chen C, et al. Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer. Int J Nanomedicine. 2016;11:5519–5529. doi:10.2147/IJN.S111594
   PubMed Web of Science ®Google Scholar
• de Resende MF, Vieira S, Chinen LT, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11(1):36. doi:10.1186/1479-5876-11-36
   PubMed Web of Science ®Google Scholar
• Gao X, Wang J, Zhang S. Integrated bioinformatics analysis of hub genes and pathways in anaplastic thyroid carcinomas. Int J Endocrinol. 2019;2019:9651380. doi:10.1155/2019/9651380
   PubMed Web of Science ®Google Scholar
• Ludvíková M, Holubec L, Ryska A, et al. Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining. Anticancer Res. 2005;25:1835–1840.
   PubMed Web of Science ®Google Scholar
• Jingni H, Zhong T, Xu Y, et al. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence. Clin Exp Metastasis. 2020;37(2):257–267. doi:10.1007/s10585-019-10011-4
   PubMed Web of Science ®Google Scholar
• Manaios L, Tsiambas E, Alevizaki M, et al. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. J BUON. 2008;13:537–541.
   PubMed Web of Science ®Google Scholar
• Karayan-Tapon L, Menet E, Guilhot J, et al. Topoisomerase II alpha and telomerase expression in papillary thyroid carcinomas. Eur J Surg Oncol. 2004;30(1):73–99. doi:10.1016/j.ejso.2003.10.002
   PubMed Web of Science ®Google Scholar
• Lin JD, Liou MJ, Hsu HL, et al. Circulating epithelial cell characterization and correlation with remission and survival in patients with thyroid cancer. Thyroid. 2018;28(11):1479–1489. doi:10.1089/thy.2017.0639
   PubMed Web of Science ®Google Scholar
• Hossain MA, Asa TA, Rahman MM, et al. Network-based genetic profiling reveals cellular pathway differences between follicular thyroid carcinoma and follicular thyroid adenoma. Int J Environ Res Public Health. 2020;17.
   PubMed Web of Science ®Google Scholar
• Pan Z, Li L, Fang Q, et al. Integrated bioinformatics analysis of master regulators in anaplastic thyroid carcinoma. Biomed Res Int. 2019;2019:9734576. doi:10.1155/2019/9734576
   PubMed Web of Science ®Google Scholar
• Hu S, Liao Y, Chen L. Identification of key pathways and genes in anaplastic thyroid carcinoma via integrated bioinformatics analysis. Med Sci Monit. 2018;24:6438–6448. doi:10.12659/MSM.910088
   PubMed Web of Science ®Google Scholar
• Zhou Z, Liu S, Zhang M, et al. Overexpression of topoisomerase 2-alpha confers a poor prognosis in pancreatic adenocarcinoma identified by co-expression analysis. Dig Dis Sci. 2017;62(10):2790–2800. doi:10.1007/s10620-017-4718-4
   PubMed Web of Science ®Google Scholar
• Zeng S, Liu A, Dai L, et al. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 2019;19(1):604. doi:10.1186/s12885-019-5814-y
   PubMed Web of Science ®Google Scholar
• An X, Xu F, Luo R, et al. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer. 2018;18(1):331. doi:10.1186/s12885-018-4170-7
   PubMed Web of Science ®Google Scholar
• Pei YF, Yin XM, Liu XQ. TOP2A induces malignant character of pancreatic cancer through activating beta-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2018;1864(1):197–207. doi:10.1016/j.bbadis.2017.10.019
   PubMed Web of Science ®Google Scholar
• Zhang R, Xu J, Zhao J, et al. Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 2018;119(9):7256–7263. doi:10.1002/jcb.26916
   PubMed Web of Science ®Google Scholar
• Sapetto-Rebow B, McLoughlin SC, O’Shea LC, et al. Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants. BMC Dev Biol. 2011;11(1):71. doi:10.1186/1471-213X-11-71
   PubMed Web of Science ®Google Scholar
• Liu ZM, Wu ZY, Li WH, et al. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67. Eur Rev Med Pharmacol Sci. 2019;23:3421–3430.
   PubMed Web of Science ®Google Scholar
• Ress AL, Stiegelbauer V, Winter E, et al. MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol Carcinog. 2015;54(11):1442–1450. doi:10.1002/mc.22218
   PubMed Web of Science ®Google Scholar
• Zhu D, Yu Y, Wang W, et al. Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway. Cancer Med. 2019;8(13):6064–6081. doi:10.1002/cam4.2494
   PubMed Web of Science ®Google Scholar